Skip to main content

Advertisement

Table 1 Design of studies conducted to evaluate the efficacy of an oral chewable tablet containing sarolaner, moxidectin and pyrantel pamoate against induced ascarid infections in dogs

From: Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced ascarid infections in dogs

StudyAscarid/Target stage (isolate origin)Treatment groupanDay of treatmentDay of inoculationbDay(s) of fecal egg countsDay of worm recovery
1Toxocara canis/immature adults (L5) (USA)Placebo80− 24na7
SAR + MOX + PYR8
SAR + MOX8
2Toxocara canis/immature adults (L5) (EU)Placebo80− 24na7
SAR + MOX + PYR8
3Toxocara canis/adults (USA)Placebo80− 49− 37
SAR + MOX + PYR8
SAR8
MOX8
PYR8
4Toxocara canis/adults (EU)Placebo80− 57− 8, − 6, − 4, − 37
SAR + MOX + PYR8
5Toxascaris leonina/adults (EU)Placebo80− 88− 8, − 6, − 4, − 37
SAR + MOX + PYR8
6Toxascaris leonina/adults (EU)Placebo80− 88− 8, − 6, − 4, − 310
SAR + MOX + PYR8
  1. aSingle oral administration providing minimum dosages of 1.2 mg/kg sarolaner (SAR), 24 µg/kg moxidectin (MOX) and 5 mg/kg pyrantel pamoate (PYR)
  2. bEach dog inoculated with L3 larvated T. canis or T. leonina eggs. In Studies 1, 2, 5 and 6 each dog was inoculated with 300 ± 50 eggs, and in Studies 3 and 4 each dog was inoculated with 250–300 (± 50) eggs
  3. Abbreviations: USA, United States of America; EU, Europe; na, not applicable